The Difference of Grey Matter Volume Among the Patients of Schizophrenia

NCT05262790 | Completed DMC

• 1 other identifier: GMV-2013
• Study Type: observational
• Target: 253
• Locations: 0 countries
• Sites: N/A

Brief Summary

Schizophrenia is a heritable complex phenotype whose symptoms can be clustered into three domains: positive symptoms, negative symptoms and cognitive impairments. Constellations of negative symptoms in SCZ are composed of diminished motivation and pleasure, such as asociality, anhedonia, and avolition, or diminished expressivity such as blunted affect and alogia. Negative symptoms are associated with decreased quality of life and poor functional outcomes. Although antipsychotics are generally effective on positive symptoms, they are poorly effective on negative symptoms Currently, there are no licensed targeted medications for negative symptoms. In view of these problems, considerable interest in identifying new treatment targets for negative symptoms has grown over the past decade. Despite intense efforts in brain imaging that have opened new opportunities for addressing these issues, the neurobiological mechanism of negative symptoms remains unclear. Structural brain measures from magnetic resonance imaging (MRI) are highly heritable and representatively have high reproducibility and low measurement error. Prior neuroimaging researches have consistently shown neuroanatomical abnormalities in the brains of individuals with SCZ, with the most robust and consistent group-level structural differences in widespread reduced volumes of hippocampal thalamus, amygdala and nucleus accumbens. SCZ have been associated with widespread structural brain abnormalities, but results from neuroimaging studies have been inconsistent.

Conditions

Schizophrenia; Neuroimaging; Cognitive Dysfunction

Outcome Measures

Primary Outcomes (3)

• GMV difference among PNS, PPS and HC groups.

  PNS、PPS and HC will undergo Magnetic Resonance Imaging (MRI) at baseline. And the GMV of the three group was collected and analysed.1)The PNS patients showed longer duration, less positive symptoms, more severe PANSS-total symptoms and negative symptoms (all p values ≤ 0.001) than PPS. 2)compared with HC group, PPS group showed reduced GMV in the right orbital gyrus.

  baseline

• Identifying genes associated with GMV alterations in PNS.

  1)PLS1 weighted gene expression profile was positively correlated with PNS vs. HC GMV difference.2)The 2 overlapping genes (GRM7, RASSF7) exhibited significant negative correlations with regional GMV alterations in schizophrenia patients with predominantly negative symptoms.

  baseline

• PPI network construction and hub gene identification.

  1)PPI analysis of hub genes revealed a network consisting of 10 connected proteins and 33 edges, which is remarkably significantly higher than the expected 2 edges.2)PPI analysis revealed a network consisting of 461 connected proteins and 706 edges, which is remarkably significantly higher than the expected 621 edges

  baseline

Study Arms (3)

PNS group

The patients with prominently negative symptoms (PNS) had a greater score on the negative than on the positive subscale of the PANSS, a negative symptoms score \> 20, and at least one of items from PANSS negative symptoms scale ≥ 4 points

Other: This is not an intervention study

PPS group

The patients with predominantly positive symptoms (PPS) had a greater score on the positive than on the negative subscale of the PANSS

Other: This is not an intervention study

Control

Healthy control

Other: This is not an intervention study

Interventions

This is not an intervention study OTHER

PNS group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Study population will include individuals with psychotic disorders (schizophrenia or schizophreniform disorder) and healthy comparison participants(without personal or family history of psychotic disorders). Participants will be women and men, all races and ethnicities. Participants with schizophrenia/schizophreniform disorder will be aged 18-60 years.

You may qualify if:

• All the patients satisfied the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-Ⅳ) diagnostic criteria for schizophrenia or schizophreniform disorder.
• Women and men
• to 60 years of age
• Able and willing to provide written informed consent; and willing to commit to the study protocol
• Able to read, speak, and understand Chinese

You may not qualify if:

• (i) were \<18 years or \>60 years
• (ii) psychotic patients in unstable clinical condition (e.g., being aggressive and uncooperative)
• (iii) had major neurological or other psychiatric disorders, or significant medical condition including neurological disease, severe cardiovascular, hepatic, renal diseases
• (iv)had MRI abnormalities, or had MRI contraindications.

Sponsors & Collaborators

• Shanghai Mental Health Center: lead

MeSH Terms

Conditions

Schizophrenia; Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Cognition Disorders; Neurocognitive Disorders

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 22, 2022
• First Posted: March 2, 2022
• Study Start: June 26, 2013
• Primary Completion: December 1, 2016
• Study Completion: January 1, 2017
• Last Updated: March 2, 2022

Record last verified: 2021-12

Data Sharing

• IPD Sharing: Will not share